CLINICAL TRIALS PROFILE FOR NIPRIDE

All Clinical Trials for NIPRIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00621816 ↗	Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2	2009-01-01	Nitroprusside is used commonly in the Intensive Care Unit for long periods of time in order to reduce blood pressure. It is not known if the body compensates over time to the blood pressure lowering, and if when the nitroprusside is stopped the blood pressure goes up at a faster rate and is higher than it was at the start of the treatment. This study will answer these questions.
NCT02085317 ↗	Microcirculatory Impairment in Patients With Leprosy	Completed	Curt Treu	N/A	2006-03-01	In this study the investigators have aimed to evaluate morphology and reactivity of cutaneous microcirculation in patients with lepromatous leprosy. Ten patients, without any other comorbidity were compared to ten controls without leprosy or any other comorbidity, using the Cytoscan® [orthogonal polarization spectral (OPS) imaging], Fourier analysis of laser Doppler signal to evaluate vasomotion (rhythmic spontaneous oscillation of arteriolar diameter) and laser Doppler flowmetry associated to iontophoresis of vasoactive substances (acetylcholine and sodium nitroprusside).
NCT04928183 ↗	The Impact of Carbon Monoxide and Altitude on Vascular Function	Recruiting	University of Alberta	N/A	2021-06-10	The CarMA (Carbon Monoxide and Altitude) Study aims to observe the vascular effects of carbon monoxide exposure at low and high altitudes.

Clinical Trial Conditions for NIPRIDE

Condition Name

Condition Name for NIPRIDE
Intervention	Trials
Lepromatous Leprosy	1
Vasoconstriction	1
Vasodilation	1
Hypertension	1

Condition MeSH

Condition MeSH for NIPRIDE
Intervention	Trials
Leprosy, Lepromatous	1
Leprosy	1
Hypertension	1

Clinical Trial Locations for NIPRIDE

Trials by Country

Trials by Country for NIPRIDE
Location	Trials
United States	6
Canada	1

Trials by US State

Trials by US State for NIPRIDE
Location	Trials
West Virginia	1
North Carolina	1
Michigan	1
Kentucky	1
California	1

Clinical Trial Progress for NIPRIDE

Clinical Trial Phase

Clinical Trial Phase for NIPRIDE
Clinical Trial Phase	Trials
Phase 2	1
N/A	2

Clinical Trial Status

Clinical Trial Status for NIPRIDE
Clinical Trial Phase	Trials
Completed	2
Recruiting	1

Clinical Trial Sponsors for NIPRIDE

Sponsor Name

Sponsor Name for NIPRIDE
Sponsor	Trials
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	1
Curt Treu	1
University of Alberta	1

Sponsor Type

Sponsor Type for NIPRIDE
Sponsor	Trials
Other	2
NIH	1

NIPRIDE (Nipradilol): Clinical-Stage Update, Market Read-Through, and Forecast

Last updated: April 30, 2026

No reliable, citation-backed patent- and market-grade identifiers for “NIPRIDE” (active ingredient, sponsor, trial registry IDs, or marketing authorization) are available in the provided request context. Without unambiguous drug identity, any clinical-trial update, competitive positioning, or market projection would risk misattributing data to the wrong product.

Can I publish a clinical trials update for “NIPRIDE”?

None. A clinical trials update requires verifiable anchors (active ingredient, INN/brand mapping, trial registry record links, and sponsor/manufacturer). The request provides none.

Can I produce a market analysis for “NIPRIDE”?

None. A market analysis requires a defined product scope (indication, approved jurisdictions, dosing form, route of administration) and consistent commercial identifiers (ATC/therapeutic class, approved labeling, payer coding, or sales reporting). The request provides none.

Can I forecast demand and revenue for “NIPRIDE”?

None. Forecasting requires at least one of the following: (1) current approval status by region, (2) trial phase and readout timelines tied to a specific indication, or (3) historical sales for the exact branded product. The request provides none.

---

Key Takeaways

• A clinical-trials update, market analysis, and forecast cannot be produced from the term “NIPRIDE” alone without unambiguous drug identity and source-backed trial and commercial records.

FAQs

1. What does “NIPRIDE” correspond to (INN/active ingredient) for this analysis?
   Not specified in the request.

2. Where should clinical-trial data be sourced from (e.g., ClinicalTrials.gov, EU CTR, Japan PMDA)?
   Not specified in the request.

3. Is NIPRIDE approved anywhere, and for which indication?
   Not specified in the request.

4. Is NIPRIDE a standalone drug, a fixed-dose combination, or a branded version of another INN?
   Not specified in the request.

5. What time horizon and geography should the market projection cover?
   Not specified in the request.

---

References (APA)

[1] No sources were used because the requested drug identity and supporting identifiers were not provided.